(23/91) of hips injected required re-injection of the same hip at a mean duration of 15.4 (range 4 -43) months post injection. Conclusions: Ultrasound guided steroid injection into the hip by a paediatric rheumatologist trained in the procedure is safe with a high rate of success. Background: Leflunomide is a widely used oral DMARD in the treatment of adults with inflammatory arthritis. It reversibly inhibits dihydroorotate dehydrogenase, the rate limiting step in pyrimidine synthesis, thus interfering with DNA synthesis, repair & cellular replication. Although previously described in literature to be a safe/ effective alternative to Methotrexate in JIA, it is not commonly used in Paediatric Rheumatology, due to a combination of factors which may include lack of familiarity with the drug leading to reluctance to prescribe, paucity of clear dosing guidelines and uncertainty regarding tolerability. Methotrexate intolerance often necessitates escalation of treatment to biologic therapy (estimated £9000 per year), which is significantly more expensive than Leflunomide (estimated approx. £200 per year). Aims: We present 3 year or longer follow up data for children with JIA treated with Leflunomide at our institution. Methods: 33 children/young people with JIA who had initiated treatment with Leflunomide between 2010 and 2014 were identified from our Paediatric Rheumatology Database. Information was collected on demography, indication for starting Leflunomide and adverse effects over a 3-7 year follow up period. Efficacy was evaluated by documenting additional treatments required after commencing Leflunomide.
Background: Leflunomide is a widely used oral DMARD in the treatment of adults with inflammatory arthritis. It reversibly inhibits dihydroorotate dehydrogenase, the rate limiting step in pyrimidine synthesis, thus interfering with DNA synthesis, repair & cellular replication. Although previously described in literature to be a safe/ effective alternative to Methotrexate in JIA, it is not commonly used in Paediatric Rheumatology, due to a combination of factors which may include lack of familiarity with the drug leading to reluctance to prescribe, paucity of clear dosing guidelines and uncertainty regarding tolerability. Methotrexate intolerance often necessitates escalation of treatment to biologic therapy (estimated £9000 per year), which is significantly more expensive than Leflunomide (estimated approx. £200 per year). Aims: We present 3 year or longer follow up data for children with JIA treated with Leflunomide at our institution. Methods: 33 children/young people with JIA who had initiated treatment with Leflunomide between 2010 and 2014 were identified from our Paediatric Rheumatology Database. Information was collected on demography, indication for starting Leflunomide and adverse effects over a 3-7 year follow up period. Efficacy was evaluated by documenting additional treatments required after commencing Leflunomide.
Results: Age at commencement of Leflunomide ranged from 6 to 18 years (mean age 12.6). 9 were male, 24 female. See Table 1 for subtypes of JIA. Initial dose was titrated by the prescribing physician according to body weight and increased in increments as tolerated. Eventual dose ranged from 5 to 20mg. Dosage regimens included daily, alternate day or weekday dosing. The main indication for starting Leflunomide was Methotrexate intolerance in 24/33 (73%) patients. It was started as an adjunct to biologic therapy in 10/33 (30%) cases. Overall, Leflunomide was well tolerated (Table 2 -reported side effects). 5/33 (15%) patients were intolerant leading to discontinuation (excluding 2 who had ongoing symptoms despite cessation). 2/33 (6%) patients developed uveitis whilst on Leflunomide. 9/33 (27%) patients required either no additional treatment or infrequent steroid joint injections. 8/9 (89%) of these patients had either persistent/extended oligo-JIA or RF negative poly-JIA. 2 patients previously intolerant to Methotrexate were able to successfully restart Methotrexate after stopping Leflunomide. Conclusions: Based on this retrospective analysis, we propose the potential use of Leflunomide as a highly cost-effective, safe, alternative oral DMARD which merits consideration in the following situations: Children with JIA (especially oligoarticular and RF negative polyarticular JIA) in whom Methotrexate intolerance is a profound problem (either Methotrexate-associated nausea or recurrent transaminitis) where escalation to biologic therapy is not justified. As an adjunct DMARD to anti-TNF therapy in children who are Methotrexate intolerant. Where Methotrexate needs to be given a drug-holiday i.e. Methotrexate intolerance might possibly abate at a later stage, thereby allowing a successful re-trial of Methotrexate In line with published data, we would not recommend the use of Leflunomide as a DMARD for children with JIA-associated uveitis. We intend to extend this study to include our entire cohort of patients on Leflunomide. Background: Tocilizumab (TCZ) is a recombinant-humanised-monoclonal-antibody that acts as an Interleukin-6-receptor-antagonist. Approved for treatment of children over 2 years with Systemic-onset JIA (SoJIA) and Poly-articular JIA (PJIA). Since 2010, TCZ has been used in the NCPR for these indications. Aims: To describe to-date NCPR experience of the use of TCZ, and reports on outcomes, efficacy and tolerability. Methods: A retrospective chart review of all children with JIA who received TCZ since its NCPR introduction in 2010. Baseline demographics recorded. Subtype of JIA documented. Prior and adjunctive treatments particularly oral steroids recorded. Completion of Pre-TCZ biologic workup reviewed. TCZ dose and infusion frequency documented. Active disease was defined by active joint count (AJC), and/or presence of raised Acute Phase Reactants (APR). At TCZ commencement Initial AJC and raised APR documented. Clinical remission defined by achievement of 0 AJC and Laboratory Remission defined by normalisation of APR. Outcome measures included clinical remission rate, laboratory remission rate, time to clinical remission and successful steroid wean. . Results: A total of 32 JIA patients (81% Females) have been treated with TCZ over the past 7 years. The majority (41%) were SoJIA, 34% PJIA (3/11 RF-positive), 12.5% Extended OligoJIA (EoJIA) and 12.5% others. Median age at diagnosis 5.7yr (1.8-12.5yrs) and Median time to commencing TCZ 4.3 yrs (0.9-10.4yrs) . Prior to TCZ, 97% of children received Methotrexate (MTX) monotherapy. Following MTX, Majority (91%) received at least two Biologics, 6% received four. All children had a full biologic workup Pre-TCZ. All had negative TB screen and 97% were varicella immune. All received TCZ fortnightly at the outset. Adjuvant steroids were required in 56% at commencement of TCZ. Complete steroid wean was achieved in 83%. Average Initial AJC was 9 (3-23joints) and APR were raised in 56%. Clinical Remission achieved in 83% (25/30) and average time to remission was 5 months (0.5-16 mo). APR normalised in 78% after one infusion, 100% after three. As a long term outcome, TCZ was continued in 78% (25/ 32), 36% (9/25) achieved and maintained reduced infusion frequency (3-8weekly). TCZ was discontinued in 22% (7/32), 3 of these children had primary loss of response and underwent stem cell transplant (HSCT), the remaining 4 had secondary loss of response and were switched to another biologic. The outcome of TCZ is variable in different JIA subtypes with best results observed in PJIA and EoJIA with 100% remission rate and 100% continuation rate. Conclusions: NCPR experience with TCZ has been positive, with high rates of remission (83%) and tolerability, 78% remaining on the drug. TCZ Improved Outcomes and Steroid Sparing in Refractory Cases. Rather than using multiple biologics, this encourages consideration of the drug earlier. Background: Uveitis in children can lead to blindness or other serious complications if there is delay or inadequate treatment Aims: Uveitis in children can lead to blindness or other serious complications if there is delay or inadequate treatment Methods: Cases with the diagnosis of uveitis identified through electronic Medical Record from 1/1/2011 to 31/6/2017 using International Classification of Disease version 10 (ICD 10 code) of H20.0, H20.011, H20.012, H20.013, H20.041, H20.042, H20.043,
THE EXPERIENCE IN CHILDREN PRESENTING WITH UVEITIS IN THE CITY OF ABU-DHABI

